Published January 29, 2026 | Version v1
Journal article Open

COMPLEMENTO, PLAQUETAS Y NETOSIS: MICROINFLAMACIÓN SILENTE EN VIH VIRORREPRIMIDO

  • 1. Universidad de Antioquia, Medellín, Colombia
  • 2. Universidad Santiago de Cali, Programa de Medicina Cali; Valle del Cauca, Colombia

Description

Tipo de artículo: Caso clínico

La persistencia de inflamación inmunometabólica en personas que viven con VIH virorreprimido constituye un desafío clínico emergente, asociado a mayor carga de comorbilidades no definitorias de SIDA y riesgo cardiovascular precoz. El objetivo de esta revisión y reporte de caso es analizar el papel fisiopatológico del eje complemento–plaquetas–NETosis (C2–C5a/C5aR–CD62P–NETs) en la activación inmunotrombótica subclínica y su relevancia diagnóstica y terapéutica. Se realizó una búsqueda narrativa estructurada en PubMed, Scopus y Web of Science, incluyendo estudios experimentales, observacionales y ensayos clínicos publicados entre 2017–2025 sobre inflamación residual, inmunotrombosis y biomarcadores del complemento en VIH controlado. Los principales hallazgos indican que, incluso bajo supresión virológica sostenida, persiste disregulación del complemento con disminución de C2 y aumento de C5a, acompañada de activación plaquetaria (CD62P-MFI) e inducción de NETosis, mecanismos que favorecen microtrombosis endotelial y enfermedad cardiovascular silenciosa. 

El caso clínico presentado ejemplifica la relevancia de estos hallazgos y la necesidad de evaluación inmunológica ampliada ante síntomas inespecíficos. Se concluye destacando el potencial clínico de biomarcadores inmunotrombóticos para estratificación individualizada y de terapias dirigidas al eje C5a/C5aR.

Abstract (English)

Article type: Clinical case

Persistent immunometabolic inflammation in virally suppressed people living with HIV (PLWH) represents an emerging clinical challenge linked to increased non-AIDS comorbidities and early cardiovascular risk. This review and case report aim to analyze the physiological role of the complement–platelet–NETosis axis (C2–C5a/C5aR–CD62P–NETs) in subclinical immunothrombotic activation and their diagnostic and therapeutic implications. A structured narrative search was conducted in PubMed, Scopus, and Web of Science, including experimental, observational, and clinical trial evidence published between 2017–2025 related to residual inflammation, immunothrombosis, and complement biomarkers in controlled HIV. Findings indicate that, despite sustained viral suppression, persistent complement dysregulation occurs with decreased C2 and elevated C5a, along with platelet activation (CD62P-MFI) and NETosis induction, promoting endothelial microthrombosis and silent cardiovascular disease. 

The presented case illustrates the clinical relevance of these mechanisms and supports expanded immunologic evaluation in PLWH with nonspecific symptoms. We conclude by highlighting the potential value of immunothrombotic biomarkers for 

Files

sanum_v10_n1_a13.pdf

Files (234.1 kB)

Name Size Download all
md5:f58a3015616a9e1774c8a54900ebc33f
234.1 kB Preview Download

Additional details

Additional titles

Translated title (English)
COMPLEMENT, PLATELETS AND NETOSIS: SILENT MICROINFLAMMATION IN VIROREPRESSED HIV

Identifiers

ISSN
2530-5468

Dates

Collected
2025-12-06
manuscrito recibido
Accepted
2026-01-16
evaluación doble ciego
Available
2026-01-29
Publicación en numero de la revista

Software

References

  • 1. Natalie T Subia, Thomas K Awamura, Logan S Dean, Keona Loftis, Louie Mar Gangcuangco, Iain MacPherson, Sandra Chang, Dominic C Chow, Cecilia M Shikuma, Juwon Park, Dysregulation of complement components associated with inflammation and coagulation in virally suppressed people living with HIV, The Journal of Immunology, Volume 214, Issue 11, November 2025, Pages 2871–2880, https://doi.org/10.1093/jimmun/vkaf227 2. Park J, Dean LS, Heckl J, Gangcuangco LM, Pedro TK, Tallquist MD, Seto TB, Shiramizu B, Chow DC, Shikuma CM. Low-density granulocytes display immature cells with enhanced NET formation in people living with HIV. Sci Rep. 2023 Aug 16;13(1):13282. doi: 10.1038/s41598-023-40475-0. PMID: 37587169; PMCID: PMC10432506. 3. Collins LF, Palella FJ Jr, Mehta CC, Holloway J, Stosor V, Lake JE, Brown TT, Topper EF, Naggie S, Anastos K, Taylor TN, Kassaye S, French AL, Adimora AA, Fischl MA, Kempf MC, Koletar SL, Tien PC, Ofotokun I, Sheth AN. Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019. JAMA Netw Open. 2023 Aug 1;6(8):e2327584. doi: 10.1001/jamanetworkopen.2023.27584. PMID: 37548977; PMCID: PMC10407688. 4. Coss SL, Zhou D, Chua GT, Aziz RA, Hoffman RP, Wu YL, Ardoin SP, Atkinson JP, Yu CY. The complement system and human autoimmune diseases. J Autoimmun. 2023 May;137:102979. doi: 10.1016/j.jaut.2022.102979. Epub 2022 Dec 18. PMID: 36535812; PMCID: PMC10276174. 5. Raposo MA, Armiliato GNA, Guimarães NS, Caram CA, Silveira RDS, Tupinambás U. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. Rev Soc Bras Med Trop. 2017 Sep-Oct;50(5):598-606. doi: 10.1590/0037-8682-0258-2017. PMID: 29160505.